Skip to Content
Hae Menu

Updated data from CheckMate 9LA in advanced NSCLC show continuing benefit

Updated data from the CheckMate 9LA study shows that nivolumab plus ipilimumab with to cycles of chemotherapy gave a significant improvement of overall survival compared to chemotherapy alone in patients with non-small cell lung cancer (NSCLC). Data supports treatment with combinations in first line advanced NSCLC.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Asiaan liittyvä sisältö

Azacitidine was generally well tolerated in patients ≥ 75 years of age in QUAZAR AML-001

/ BestPractice Nordic
EHA21AML

CAR-T cell therapy provides early and deep response in multiple myeloma patients

/ BestPractice Nordic
myeloomaEHA21

mutNPM1 status is a prognostic and an independent predictive marker for improved survival with azacitidine

/ BestPractice Nordic
EHA21AML
Back to top